Rs 118 se Rs 541 ye sirf ek saal ki kahani hai BLISSGVS ki. Bliss GVS Pharma ek aisi company hai jiske baare mein zyada logo ko pata nahi tha, lekin pichle 12 mahino mein 230%+ return ne ise suddenly radar par la diya hai.
BLISSGVS Share Price Target 2026 To 2030
| Year | Target Price (Rs.) Approx |
|---|---|
| 2026 | 380 – 650 |
| 2027 | 480 – 850 |
| 2028 | 600 – 1,100 |
| 2029 | 750 – 1,400 |
| 2030 | 950 – 1,800 |
Ye targets maine current price Rs 530, Q4 FY26 ke record results, African healthcare market ki structural growth, contract manufacturing expansion aur WHO GMP compliance track record ko dekhte hue estimate kiye hain. Ye guaranteed returns nahi hain. African regulatory delays, ASM list ka overhang ya currency risks se targets achieve hone mein time lag sakta hai. Live price ke liye NSE India dekhna better rahega.Live price ke liye NSE India aur detailed financials ke liye Screener.in dekhna better rahega, agar aap log stock related koi bhi calculation use karna ho to Calculators use kar sakte hai.
BLISSGVS Share Price Target 2026
2026 ke liye Rs 380-650 ka range main de raha hu. Stock Rs 541.10 ka all-time high bana chuka hai June 29, 2026 ko aur abhi Rs 530 ke aaspaas consolidate kar raha hai. ASM yaani Additional Surveillance Measure list mein hone ki wajah se volatility naturally zyada hai, lekin Q4 FY26 ke strong numbers – 129% PAT jump – ek solid fundamental base provide karte hain. Rs 1 per share dividend July 8 ko aane wala hai. Agar FY27 Q1 results bhi strong aaye to 2026 mein upper range test ho sakta hai.
ALSO READ-Vedanta Power Share Price Target 2026 To 2030
BLISSGVS Share Price Target 2027
2027 ke liye Rs 480-850 ka range realistic lagta hai. Company ka revenue 5-year CAGR sirf 3.04% raha hai industry average 10.39% se kaafi kam, lekin recent quarters mein acceleration clearly visible hai. Agar ye revenue growth acceleration FY27 mein bhi continue rahi aur African market recovery strong rahi to 2027 mein meaningful re-rating ho sakti hai. WHO prequalification lists expand hone se naye addressable markets bhi open ho sakte hain.
ALSO READ-IFCI Limited Share Price Target 2026 To 2030
BLISSGVS Share Price Target 2028
2028 ke liye Rs 600-1,100 ka range estimate karta hu. Africa mein healthcare budgets structural basis par badh rahe hain aur government tenders aur institutional procurement ke through pharmaceutical demand consistently grow kar rahi hai. Bliss GVS ki Palghar manufacturing facility expansion bhi 2028 tak full capacity par operate kar rahi hogi. European market mein Asterisk Lifesciences ke through penetration bhi tab tak meaningful ho sakti hai.
ALSO READ-Inox India Share Price Target 2026 To 2030
BLISSGVS Share Price Target 2029
2029 ke liye Rs 750-1,400 ka range dekhta hu. Sub-Saharan Africa ka private healthcare network jo ab tezi se expand ho raha hai 2029 tak ek substantial size tak pahunch chuka hoga, jisme branded generics ki demand significantly badhi hogi. Regulatory harmonisation across African markets bhi tab tak puri tarah implement hogi jo Bliss GVS jaise WHO GMP certified players ke liye market access easier banayegi.
Expert Recommended Share Market Books
Price Action Trading (English Book) – Link
Master Price Action Trading – 51 Days Live Trading Examples- Link
Ye books Amazon ya Flipkart par easily mil jaati hain. Investing mein paisa lagane se pehle knowledge lagana sabse zaroori hai.
BLISSGVS Share Price Target 2030
2030 tak ke liye Rs 950-1,800 ka range main estimate karta hu. Agar company apna contract pharmaceutical manufacturing segment aggressively scale kar paayi aur innovator companies ke outsourcing deals secure kiye to ye targets achievable hain. Africa mein rising middle class aur expanding healthcare coverage ek multi-decade tailwind hai. Lekin ye sab execution par depend karega aur African regulatory environment kisi ek country mein issue aaya to – jaise Ghana mein pehle hua tha – sentiment kharabb ho sakta hai.
BLISSGVS Future Growth Plans
Company apni multi-product facility Palghar, Maharashtra mein expand kar rahi hai jo WHO GMP, EU GMP, ISO 14001 aur OHSAS 45001 standards par certified hai. Ye manufacturing capability future orders ke liye backbone hai.
Kenya, Nigeria, Ghana aur France mein existing presence ko aur deepen karna ek priority hai. Asterisk Lifesciences Limited UK subsidiary ke through European market mein registrations aur marketing ka kaam chal raha hai jo future mein ek new revenue stream ban sakta hai.
Contract manufacturing segment globally tezi se grow kar raha hai kyunki innovator companies increasingly specialized dosage form production outsource kar rahi hain. Bliss GVS ke paas ye capability hai – suppositories, soft gelatin capsules aur antimalarial formulations kuch unique dosage forms hain jo ye company effectively banati hai.
Latest News Affecting BLISSGVS Share Price
June 29, 2026 ko stock Rs 491.90 par open hua aur Rs 541.10 ka all-time high banaya pichli close Rs 492 se ek bada jump. Aaj stock Rs 526-530 ke range mein settle hua. Q4 FY26 mein net profit 128.96% jump karke Rs 35.58 crore hua jabki Q4 FY25 mein sirf Rs 15.54 crore tha. Revenue 29.80% badhkar Rs 256.99 crore raha.
Board ne May 12, 2026 ko Rs 1 per share final dividend recommend kiya hai jo July 8, 2026 ko pay hoga. February 10, 2026 ko Rs 0.50 per share interim dividend bhi diya gaya tha.
6 mahine mein 215.8% aur 1 saal mein 230.59% return ye stock clearly momentum mein hai. Trendlyne ke mutabik stock “Strong Performer, Getting Expensive” category mein hai quality aur technicals strong hain lekin valuation thoda stretched hai.
Company Overview of BLISSGVS Pharma Limited
Bliss GVS Pharma Limited originally 1984 mein Mumbai mein Bliss Chemicals Pharmaceuticals India Private Limited ke roop mein incorporate hua tha aur 1985 mein operations shuru kiye. May 12, 2006 ko naam Bliss GVS Pharma Limited hua. Company pharmaceutical formulations develop, manufacture, market aur export karti hai.
Company Sub-Saharan Africa mein antimalarial, antifungal, antibacterial, anti-inflammatory aur antibiotic segments mein specialist hai. Manufacturing facility Palghar, Maharashtra mein hai jo WHO GMP approved hai aur five production facilities hain jo WHO GMP, EU GMP, ISO 14001 aur OHSAS 45001 standards follow karte hain.
July 26, 2010 ko BSE aur NSE par listed hua. Chairperson Subramanian R Vaidya hain. AGM July 15, 2026 ko scheduled hai. Company ke baare mein aur jaankari ke liye Bliss GVS Pharma Official Website dekh sakte hain.
BLISSGVS Shareholding Pattern
| Category | Holding (%) – March 2026 |
|---|---|
| Promoters | 35.36% |
| FIIs | 5-6% |
| DIIs / Mutual Funds | 8-10% |
| Public / Retail | 48-50% |
BLISSGVS Dividend History
FY26 ke liye total dividend Rs 1.50 per share ho gaya hai – Rs 0.50 interim February 2026 mein aur Rs 1.00 final jo July 8, 2026 ko pay hoga. Dividend yield 0.41% ke aaspaas hai jo high price ki wajah se low lagta hai lekin company consistent dividend pay karti hai.
BLISSGVS Bonus Share and Split History
Company ke historical corporate actions mein dividends primary focus rahi hai. Koi recent major bonus issue ya stock split nahi hua hai. Future mein agar stock Rs 600-700+ tak pahuncha to retail participation improve karne ke liye split possible hai.
BLISSGVS Competitors in India
African export-focused pharmaceutical segment mein competition growing hai.
| Competitor | Type |
|---|---|
| Ipca Laboratories | Large Listed Player |
| Ajanta Pharma | Listed Mid-cap |
| Neuland Laboratories | Listed Mid-cap |
| Sai Parenterals | Listed Small-cap |
| Corona Remedies | Listed Small-cap |
BLISSGVS – Strengths
Q4 FY26 mein PAT 129% jump genuinely impressive hai. 6 mahine mein 215% aur 1 saal mein 230% return ek strong momentum dikhata hai. Sub-Saharan Africa mein long established presence aur brand recognition ek durable competitive advantage hai. WHO GMP certification globally respected hai aur contracts secure karne mein help karta hai.
Antimalarial, antifungal jaise specialized dosage forms mein expertise ek niche moat hai. USD 111.40 million Aon contract historically secured hua tha jo company ka execution capability dikhata hai. African healthcare spending structural basis par badh rahi hai rising government budgets, WHO prequalification expansion aur private healthcare network growth teeno factors long term demand support karte hain.
BLISSGVS – Weaknesses
5-year revenue CAGR sirf 3.04% hai jabki industry average 10.39% hai ye long term underperformance concerning hai. Market share 5 saal mein 0.29% se 0.2% ho gayi competitors se zyada slow growth hai.
ROE sirf 6.74% hai jo capital efficiency ke liye weak number hai. Promoter holding 35.36% relatively low hai. ASM list mein hona circuit limits aur regulatory attention create karta hai. African regulatory risk real hai Ghana jaisi situations kisi bhi African market mein repeat ho sakti hain jaise pehle hua tha.
Risks Before Investing in BLISSGVS Stock
ASM yaani Additional Surveillance Measure list mein hona sabse immediate risk hai jo tight circuit limits aur enhanced surveillance create karta hai. Koi bhi negative news se sharp correction aa sakta hai limited exit window ke saath.
African regulatory delays ya registration issues kisi specific country mein directly revenue ko impact kar sakte hain. Currency risk real hai – African currency depreciation ya USD-INR movement profitability affect kar sakti hai.
5-year revenue growth consistently low rahi hai industry se – fundamental business execution pe sawaal bana rehta hai despite recent quarters ki improvement. Promoter holding 35% low hai. Valuation PE 53x par stretched hai recent rally ke baad.
Is BLISSGVS Share Good to Buy?
Abhi ka scenario aisa hai – ek genuinely improving business hai Africa exposure ke saath, recent quarters mein strong results hain, lekin 230% rally ke baad valuation stretched hai aur ASM list mein hone se volatility elevated hai. Jo log Rs 118-150 zone mein hold kar rahe hain unke liye ye ek exceptional journey rahi hai. Fresh entry ke liye abhi Rs 530 par full position banana risky lagta hai ek meaningful correction ka wait better strategy hogi. Rs 380-420 zone better risk-reward dega.
Is BLISSGVS Share Good for Long-Term Investment?
Long term mein Africa ki healthcare story genuinely compelling hai. Rising government budgets, WHO prequalification expansion, private healthcare network growth ye sab structural tailwinds hain. Lekin company ko apni 5-year revenue CAGR jo industry se kaafi peeche thi use consistently improve karna hoga. 3-5 saal ki horizon ke saath small allocation reasonable hai.
Is BLISSGVS Share Good for Short-Term Investment?
Short term mein ASM status hone ki wajah se circuit limits tight hain. Momentum strong hai lekin 230% rally ke baad profit booking ka risk bhi real hai. Short term traders ke liye strict stop loss absolute necessity hai.
Is BLISSGVS Better for Dividend Investors or Growth Investors?
Primarily growth play hai ye stock, lekin dividend bhi consistent deta hai. Rs 1.50 total FY26 dividend aur yield 0.41% income investors ke liye much attractive nahi hai. Growth investors ke liye Africa healthcare story compelling hai, lekin valuation aur revenue growth consistency dekhni hogi.
BLISSGVS Share Price Target Based on Technical Analysis
| Level Type | Price Zone (Rs.) |
|---|---|
| 52-Week Low | 118 |
| Strong Support | 380 – 420 |
| Previous Resistance | 462.80 |
| Current Price (June 29) | 526 – 530 |
| All Time High (Today) | 541.10 |
| Immediate Resistance | 541 – 550 |
| Strong Resistance | 600 – 620 |
BLISSGVS Share Price Target Based on Fundamental Analysis
Q4 FY26 mein revenue Rs 256.99 crore yaani 29.80% YoY growth aur net profit Rs 35.58 crore yaani 128.96% jump raha. Market cap Rs 5,217 crore hai. PE ratio 53.94x hai. PB ratio 4.52x hai. EPS TTM Rs 9.30 hai. Book value Rs 109.20 hai. Dividend yield 0.41% hai. ROE 6.74% modest hai.
1 saal return 230.59%, 6 mahine mein 215.8% aur 3 saal mein 472.15%. 5-year revenue CAGR 3.04% industry average 10.39% se kaafi kam hai jo long term concern hai.
Expert Opinion on BLISSGVS Share
Ye stock ek fascinating contradiction hai. Ek taraf Q4 FY26 mein 129% profit jump aur 230%+ 1-year return genuinely strong momentum. Doosri taraf 5-year revenue CAGR industry se kaafi neeche, market share decline aur ROE sirf 6.74% jo suggest karta hai ki business fundamentally utna efficient nahi hai jitna price suggest kar raha hai. Africa healthcare story genuinely compelling hai aur company ka niche positioning WHO GMP approved, specialized dosage forms ek real moat hai. Lekin abhi ke Rs 530 ke levels par fresh entry karna juldabaazi hogi when ASM status, thin margins aur historical underperformance in mind rakhen. Main ise maximum 3-4% allocation ke saath dekhna chahunga aur Rs 380-420 ke correction zone par entry better rahegi.
Conclusion
BLISSGVS ka ye rally ek interesting pharmaceutical export story ko highlight karta hai jo Africa ke healthcare expansion se directly linked hai. Q4 FY26 ke strong numbers aur consistent dividend dono positive signals hain. Lekin 230% rally ke baad valuation stretched hai, ASM list mein hona ek concern hai aur historical revenue growth consistency pe sawaal hai. Jo log long term Africa healthcare theme par believe karte hain unke liye ye ek small allocation ke saath watchlist worthy stock hai. Correction hone par better entry milegi.
Frequently Asked Questions
Q1. BLISSGVS share price target 2026 kya hai?
Rs 380-650 ka range realistic hai 2026 ke liye. Abhi stock Rs 530 par hai aur aaj Rs 541.10 ka all-time high banaya.
Q2. BLISSGVS share price target 2027 kya hai?
2027 ke liye Rs 480-850 ka range estimate hai agar African market recovery continue rahi aur revenue growth acceleration maintain hui.
Q3. BLISSGVS share price target 2028 kya hai?
2028 ke liye Rs 600-1,100 ka range reasonable hai jab Palghar facility full capacity par aur European market meaningful ho jaaye.
Q4. BLISSGVS share price target 2029 kya hai?
2029 ke liye Rs 750-1,400 ka range tabhi achieve hoga jab Sub-Saharan Africa ka healthcare budget expansion clearly visible revenue mein aaye.
Q5. BLISSGVS share price target 2030 kya hai?
2030 ke liye Rs 950-1,800 ka range estimate hai agar company contract manufacturing segment aggressively scale kar paayi.
Q6. BLISSGVS ka 1 saal mein kitna return hua?
1 saal mein 230.59% return hua hai. 52-week low Rs 118 se aaj Rs 530 tak – genuinely multibagger journey.
Q7. BLISSGVS ASM list mein kyun hai?
Stock ASM yaani Additional Surveillance Measure list mein hai 230%+ rally ke baad regulatory monitoring ki wajah se. Iska matlab hai tight circuit limits aur enhanced surveillance.
Disclaimer
Main SEBI registered advisor nahi hu. Ye article sirf educational purpose ke liye likha gaya hai. Stock market mein invest karne se pehle apni khud ki research zaroor karein aur agar zaroorat lage to qualified financial advisor se salah lein. Kisi bhi profit ya loss ki zimmedari meri nahi hogi.